LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment
Key facts
- Who runs it
- University of North Carolina, Chapel Hill
- Where
- Chapel Hill, United StatesSee the location
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 68 people, planned
- Started
- Nov 2026
- Expected to end
- 30 Apr 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- LM11A-31
- Placebo
- Record updated
- 18 November 2026
Who can take part
- Age
- 50 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Women and men of any race or ethnicity, aged 50-75 years, inclusive
- Have capacity to provide informed consent, as demonstrated with a capacity screening tool
- Sign informed consent form (ICF)
- Evidence of Human Immunodeficiency Virus (HIV) infection. If unavailable in the participant's medical record, HIV infection will be confirmed using a point-of-care antibody test (MedMira Rapid Test, Canada). If the result differs from the participant's self-report, a clinical HIV antigen-antibody assay will be performed
- Stable antiretroviral therapy (ART) regimen for at least 1 year with plasma HIV ribonucleic acid (RNA) ≤ 40 copies/mL at screening and for at least 6 months
- Cluster of Differentiation 4 (CD4)+ T-cell count > 350/microliter (μL)
- Mild to moderate neurocognitive impairment (NCI), defined as a Brain Baseline Assessment of Cognition and Everyday Functioning (BRACE) and global T score from a full 7 domain neurocognitive test battery that is at least 1 standard deviation below age- and sex-standardized norms
- For women of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to treatment initiation. Women of childbearing potential as well as male study participants with partners of childbearing potential must use a suitable barrier method (e.g., male condom) in conjunction with a highly effective form of contraception, while receiving the protocol-specified treatment and for 90 days after stopping; Women of childbearing potential (WOCBP) are defined as women who have experienced menarche and are neither postmenopausal nor permanently sterile. Permanent sterility includes prior hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. Postmenopausal status is defined as at least 12 consecutive months without menstruation, with no alternative medical explanation for the amenorrhea; No sperm donations should be made from a participant while on study drug and for 90 days after stopping study drug
Who cannot take part
- Neurological conditions other than HIV disease that may affect study outcomes. Exclusionary neurological conditions include: head injury with loss of consciousness for more than 30 minutes or resulting in neurologic complications; poorly controlled or untreated seizure disorder; Alzheimer's Disease (AD) and related dementias, demyelinating diseases, a history of stroke, an intracranial mass lesion and other non-HIV neurological disorders that in the opinion of the study clinician would lead to impaired cognition; o Note: The comprehensive medical evaluations, which includes a careful history and standardized neurologic examination, will collect symptoms and signs of any prior clinically significant cerebrovascular events, such as unilateral upper motor neuron pattern weakness, visual field defect, or hyperreflexia
- Any illicit drug use as demonstrated on drug screening, except cannabis
- Participants who are receiving any of the following medications should be excluded due to potential interactions with the study measures (i.e., chronic daily drug intake of ≥ 14 days or expected for ≥14 days):; Centrally active drugs that in the opinion of the physician may affect cognitive performance (e.g., clonidine, l-methyl dihydroxyphenylalanine (DOPA), guanidine, guanfacine, etc.); Opioid containing analgesics
- Current or past severe central nervous system (CNS) infection (e.g., cryptococcal meningitis, toxoplasmic encephalitis)
- Clinically significant psychiatric disorder that could make study participation problematic or unsafe. Exclusionary psychiatric disorders include:; Untreated major depressive disorder, schizophrenia or bipolar disorders and lifetime history of schizophrenia or other psychotic disorders; Severe depression or suicidal intent on the Patient Health Questionaire-9 (PHQ-9) or Columbia-Suicide Severity Rating Scale (C-SSRS)
- Current substance use disorder (dependence of abuse) as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria. Exclusionary substance use includes: DSM-V-diagnosed alcohol use disorder (moderate or severe) within the past 12 months and, for other substances (except nicotine), moderate or severe substance use disorder within the past 5 years, or a mild substance use disorder within the past 6 months
- Current serious illness requiring systemic treatment or hospitalization
- Any significant medical conditions that would put the individual at risk to participate, based on medical history, clinical examination, or any other protocol screening assessments. Exclusionary medical conditions include: significant renal insufficiency, unstable hypertension, unstable angina, poorly controlled diabetes mellitus, unstable cardiac arrhythmias, severe coronary artery disease, severe peripheral vascular disease, severe hepato-gastrointestinal disease, and oxygen-requiring chronic pulmonary disease
- Untreated coinfection with hepatitis C virus (HCV), hepatitis B virus (HBV), or Treponema pallidum
- Pre-existing gastrointestinal conditions:; Active or poorly controlled inflammatory bowel disease, including Crohn's disease or ulcerative colitis, or active microscopic colitis; Ongoing infectious diarrhea, including unresolved Clostridioides difficile infection or another suspected or confirmed gastrointestinal infection; Persistent or recurrent diarrhea at screening that limits usual daily activities, requires ongoing treatment but remains inadequately controlled, or is accompanied by dehydration, clinically significant electrolyte abnormalities, or unintentional weight loss; Clinically significant malabsorption, short-bowel syndrome, or a high-output ostomy associated with difficulty maintaining hydration, electrolyte balance, or adequate nutrition; Active or history of gastrointestinal bleeding, unresolved bowel obstruction, or unresolved complications of gastrointestinal surgery; Any other gastrointestinal condition for which the clinical principle investigator (PI) and safety officer document that additional diarrhea would pose an unacceptable risk
- Screening will include documentation of usual stool frequency and consistency, current gastrointestinal symptoms, relevant diagnoses and surgery, medications, hydration status, and available electrolyte and renal function results. Additional evaluation will be obtained when clinically indicated. Participants with an acute, potentially reversible condition will not be enrolled while the condition remains active. Rescreening may be considered after documented resolution and confirmation that all eligibility criteria are met. A history of a gastrointestinal diagnosis or surgery alone will not automatically exclude a participant if the condition is stable and none of the above criteria apply. Uncertain cases will require documented review by the clinical PI and safety officer before enrollment. These criteria will supplement the existing general medical exclusions
- Any of the following laboratory findings at Screening:; Alanine aminotransferase >2 x upper limit of normal (ULN), aspartate aminotransferase >2 x ULN, and/or total bilirubin >1.5 x ULN; Note: Isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%; Creatinine clearance ≤ 45 min/mL (measured or calculated based on institutional standards); Eosinophil count >500 cells/µL
- For optional lumbar puncture (LP) procedure only. These criteria will not exclude participants from the study but will exclude them from undergoing option LP:; Prior adverse effect (AE) due to an LP (i.e., prior post-LP headache that did not resolve within 3 days or required blood patch); Safety contraindications to LP (e.g., bleeding diathesis, anticoagulant use); Requirements for LP: platelet count ≥50,000/µL, International Normalized Ratio (INR) <1.5, and Prothrombin Time (PT) within the performing laboratory's normal reference range. An LP will not be performed if any of these requirements is not met; For clinically stable participants, these laboratory assessments will be obtained within 14 calendar days before each LP. If an intervening illness, bleeding concern, medication change, or concern about changing laboratory values arises, the participant will undergo clinical reassessment and repeat laboratory testing within 24 hours before the procedure. The LP will be deferred until the results meet eligibility criteria and the procedural clinician determines that it is appropriate to proceed; Before each LP, the procedural clinician will document review of the laboratory results, bleeding history, and medications that may increase bleeding risk. Medication-related contraindications and other LP safety exclusions will continue to apply. These requirements will be finalized with the study clinicians at both sites and incorporated consistently throughout the protocol. Participants who are ineligible for the optional LP may remain in the main study if they otherwise meet study eligibility criteria; The investigators will exclude participants with suspected intracranial space-occupying lesions from the optional LP procedure. The investigators will review relevant history, neurological findings with a neurological examination performed by a licensed clinician and available neuroimaging. Optional research magnetic resonance imaging (MRI) participation will not substitute for clinically indicated pre-LP imaging; A neurological examination, including fundoscopy will be performed by a qualified licensed clinician before every optional LP to assess for signs of raised intracranial pressure or other neurological contraindications. A normal funduscopic examination alone will not be considered sufficient to rule out raised intracranial pressure
- Pregnancy or breast-feeding
- For optional magnetic resonance imaging (MRI) only: Safety contraindications identified on MRI safety screening (e.g., implanted metal, stents, or other devices), based on institutional guidelines
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Hiv-associated neurocognitive disorder
1 location in United States
- University of North Carolina School of Medicine, Clinical and Translational Research CenterUnitChapel Hill, United StatesContact: Marleny, Clinical Research Coordinator, BSNot yet recruiting
What happens in this trial
What the trial wants to find out
HIV rapidly infects the nervous system resulting in chronic infection that persists even when blood HIV is undetectable. The resulting inflammation causes progressive neuronal damage leading to cognitive decline in up to 50% of people living with HIV. The damage to the nervous system is due in part to a loss of natural processes that protect the brain. There are currently no effective treatments. A novel new drug, LM11A-31, has been shown to restore the protective processes thereby shifting the balance from degenerative to protective activity. Beneficial effects have been seen in patients with Alzheimer's disease and research indicates that it should have similar beneficial effects in people living with HIV. The proposed study will establish the safety and tolerability of LM11A-31 treatment in a small cohort of stable virally-suppressed participants with HIV and mild neurocognitive impairment. The focus will be on individuals 50-75 years of age who are most vulnerable for cognitive decline. To provide sufficient time to stabilize brain activity, participants will take tablets twice daily over a period of 48 weeks. The main focus of the trial will be on safety but will also be supplemented with exploratory characterization of biomarkers to confirm a reduction in degeneration as well as to provide early identification of individuals at risk for neurodegeneration. These studies are expected to show that LM11A-31 is safe to use in people living with HIV and to provide preliminary data indicating protection from neuronal damage and cognitive decline.
The 2 groups in the trial
- LM11A-31, followed by PlaceboExisting treatment, for comparison
LM11A-31 administered orally in the form of tablets for 24 weeks. Then placebo oral tablets identical to the active compound taken for 24 weeks.
Treatment: LM11A-31 and Placebo
- Placebo, followed by LM11A-31Placebo, for comparison
Placebo oral tablets identical to the active compound taken for 24 weeks. Then LM11A-31 administered orally in the form of tablets for 24 weeks.
Treatment: LM11A-31 and Placebo
How to apply
You apply to the study team, and only they decide who can take part. Talk to your doctor first.
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team to apply or to ask a question. Their contact details are in the registry record, under Contacts and Locations.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study to Establish Safety, Tolerability and Feasibility of LM11A-31 as a Neuroprotective Agent in Aging People Living With HIV and Neurocognitive Impairment on Antiretroviral Therapy
- Criteria questions
- Built from NCT07934186, who can take part
- Record updated
- 18 November 2026